Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction-Reference-Cited by-同舟云学术

Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction

Published:2022-11-01 Issue:5 Volume:323 Page:H892-H903
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

de Couto Geoffrey¹,Mesquita Thassio¹^ORCID,Wu Xiaokang¹^ORCID,Rajewski Alex²^ORCID,Huang Feng¹,Akhmerov Akbarshakh¹^ORCID,Na Na¹^ORCID,Wu Di²^ORCID,Wang Yizhou²^ORCID,Li Liang¹,Tran My¹,Kilfoil Peter¹,Cingolani Eugenio¹,Marbán Eduardo¹

Affiliation:

1. Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California

2. Applied Genomics, Computation and Translational Core, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, California

Abstract

We tested the concept that inflammation of endothelial cells is a major pathogenic factor in HFpEF. CDCs are heart-derived cell products with verified anti-inflammatory therapeutic properties. Infusion of CDCs reduced oxidative stress, restored eNOS abundance, lowered monocyte levels, and rescued the expression of multiple disease-associated genes, thereby restoring vascular reactivity. The salutary effects of CDCs support the hypothesis that inflammation of endothelial cells is a proximate driver of HFpEF.

Funder

American Heart Association

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00287.2022

Reference55 articles.

1. Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials

2. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction